Reduction in hospitalisations with dupilumab in Japanese adults with atopic dermatitis in a real‐world setting
Abstract Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations. Objectives We studied the impact of dupilumab on health care resource utilisation...
Main Authors: | Ken Igawa, Hiroyuki Fujita, Yuki Tajima, Robert Lubwama, Moataz Daoud, Zhixiao Wang, Kazuhiko Arima |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | JEADV Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1002/jvc2.151 |
Similar Items
-
Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance
by: Hidehisa Saeki, et al.
Published: (2023-06-01) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01) -
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020-05-01) -
Dupilumab side effect in a patient with atopic dermatitis: a case report study
by: Albader SS, et al.
Published: (2019-05-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)